A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2 ; volume:13 ; number:1 ; year:2021
EMBO molecular medicine / European Molecular Biology Organization ; 13, Heft 1 (2021)

Creator: Simonis, Alexander
Theobald, Sebastian J.
Fätkenheuer, Gerd
Rybniker, Jan
Malin, Jakob J.

DOI: 10.15252/emmm.202013105

URN: urn:nbn:de:101:1-2021030313025481032414

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Simonis, Alexander
Theobald, Sebastian J.
Fätkenheuer, Gerd
Rybniker, Jan
Malin, Jakob J.

Other Objects (12)

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor

Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with activity against SARS-CoV-2

Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2

Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants

Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain

Related objects

Reset password